HC Wainwright Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price reduced by stock analysts at HC Wainwright from $20.00 to $10.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the company. Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Down 12.2 %

NASDAQ ZNTL opened at $1.66 on Wednesday. Zentalis Pharmaceuticals has a 52 week low of $1.66 and a 52 week high of $18.07. The firm has a 50 day moving average of $2.97 and a two-hundred day moving average of $3.29. The stock has a market capitalization of $118.29 million, a PE ratio of -0.67 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, equities research analysts expect that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares during the last quarter. GSA Capital Partners LLP increased its position in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares in the last quarter. Verition Fund Management LLC raised its stake in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the last quarter. Primecap Management Co. CA boosted its stake in shares of Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth about $78,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.